HOPA has rolled out an enhanced IRC program that features tiered participation levels to allow companies of all sizes to participate as well as many new benefits that greatly enhance your organization’s opportunity to engage with HOPA.
Why Connect with HOPA?
The HOPA Industry Relations Council participants are comprised of pharmaceutical and medical device companies who are interested in connecting in a more significant way with key leaders in hematology/oncology pharmacy.
It is designed to:
• Provide a format for establishing and building relationships
• Foster open dialogue among key industry representatives who have ties to the specialty of hematology/oncology pharmacy
• Gain greater understanding of mutual areas of interest
• Further programs that promote optimal, cost-effective care for patients affected by cancer
We invite you to participate in the HOPA Industry Relations Council Program and receive the following new benefits:
• Opportunity to conduct advisory board with HOPA member experts in select topics
• One on One meeting with a set agenda for company representatives to engage with HOPA’s Board to identify areas of strategic importance for both parties
• Listing of Patient Assistance Programs on a special section of HOPA’s website
• Listing of key clinical trials with quarterly updates
Here are some highlighted benefits that will allow you to have access to the HOPA members.
Opportunity to conduct an advisory board with HOPA member experts
Each IRC Premier participant would have an opportunity to conduct an advisory board during one of the following venues: HOPA Annual Conference, HOPA Practice Management Program, HOPA Headquarters. HOPA would provide a list of HOPA members, who have self-identified as meeting the criteria provided by the IRC participant, including the person’s name and CV, meeting space, and audio visual.
A seat at the Industry Relations Council Annual Summit
Meet with HOPA leaders to exchange ideas and knowledge. This meeting is designed to facilitate an ongoing dialogue between industry and HOPA leaders about strategic goals and initiatives. A unique opportunity for open discussion on key topics and future trends in the specialty of hematology/oncology pharmacy, this meeting is a forum for exploring how both the association and industry can capitalize on each other’s strengths to enhance the care of patients with cancer. Each company will have up to four seats (depending upon level of participation) at the Industry Relations Council Annual Summit, and invitations will be sent to a designated contact. HOPA Board and industry representatives will convene for a 1-day meeting in Chicago.
One-on-One meeting with HOPA Board
Each IRC Premiere participant would have an opportunity to meet one-on-one (company) with the HOPA Board at one of the following venues: HOPA Annual Conference, Company Headquarters, ASCO, or at the HOPA Headquarters.
High visibility with HOPA members
Receive recognition as a participant in the Industry Relations Council annually in HOPA website, newsletter, and in the program book and signage at the HOPA Annual Conference. This recognition will be distinct and separate from recognition of commercial supporters of the conference.